Why the study?
Does losartan improve cardio-renal function and reduce oxidative stress in STZ-induced diabetic rats?
Does losartan improve cardio-renal function and reduce oxidative stress in STZ-induced diabetic rats?
In a rat model of STZ-induced diabetes, losartan attenuated cardiac and renal fibrosis and improved cardio-renal function by reducing oxidative stress and down-regulating TGF-b1 and NADPH oxidase subunits.
Hypothesis-generating for losartan in diabetic cardiomyopathy models; clinical translation remains untested.
The important role of renin-angiotensin-aldosterone system blockade in the treatment of diabetes-induced cardiomyopathy and nephropathy has been clearly established. The present study examined the effect of angiotensin II type 1 receptor blocker (ARB) losartan on oxidative stress and cardio-renal function in streptozotocin (STZ)-induced diabetic rats. Losartan treatment resulted in improvement of myocardial function and suppressed cardiac and renal fibrosis compared with the diabetic group. Losartan treatment also down-regulated transforming growth factor-beta1 expression and attenuated the increased expression levels of p22(phox) and Nox4. Blood urea nitrogen (BUN) and urinary protein levels were increased significantly in the diabetic group. Losartan treatment significantly reduced proteinuria but not BUN level. Moreover, the elevated level of malondialdehyde in both heart and kidney were significantly reduced in the losartan-treated group compared with the diabetic group. These results provided evidence that oxidative stress plays a major role in diabetic rats induced by STZ, and treatment with the ARB might be beneficial for preventing the development and progression of diabetic disease.
No takes yet. Share an insight, caveat, or question.
Arozal et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: